Sepsis Pipeline Review and Epidemiology Forecasts in New Market Research Reports

PUNE, India, November 18, 2015 /PRNewswire/ --

ReportsnReports.com adds Sepsis - Pipeline Review, H2 2015 market research report reviewing key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects.

Complete report on sepsis pipeline spread across 205 pages, talking about 36 companies, 85 drug profiles and supported with 64 tables and 15 figures is now available at http://www.reportsnreports.com/reports/435361-sepsis-pipeline-review-h2-2015.html.

This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects.

Companies discussed in this report includes Chiesi Farmaceutici SpA, Chiome Bioscience, Inc., Cilian AG, Cognosci, Inc., Diomune S.L, Endacea, Inc., Evec, Inc., Huons Co., Ltd., Immune Response BioPharma, Inc., Immunethep, SA, ImmunNovative Developments SL, InflaRx GmbH, Integrated BioTherapeutics, Inc., ISU ABXIS Co.,Ltd., Lead Discovery Center GmbH, Navigen Pharmaceuticals, Inc., Novadiscovery SAS, Ocata Therapeutics, Inc., OncoImmune, Inc., Opsona Therapeutics Limited, ProThera Biologics, LLC., Ribomic Inc., Silence Therapeutics Plc, Stemedica Cell Technologies, Inc., Syntiron LLC, Takeda Pharmaceutical Company Limited, TiGenix NV, VBS Pharmaceuticals and XImmune AB.

Order a copy of this sepsis pipeline report at http://www.reportsnreports.com/Purchase.aspx?name=435361

Drug Profiles mentioned in this report are 3K3A-APC, 7-H9, AB-022, AcPepA, adrecizumab, Alpha B Crystalline, ALT-836, AM/AMBP-1, Aspidasept, Atu-111, bacterial sepsis vaccine, BaxB-01, BaxG-03, BaxM-159, BRL-44408, BTZO-2, CAR Peptide, ceftaroline fosamil, CN-16  ,COG-133, Cx-611, Drug for Sepsis, Drugs for Sepsis, Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders, Drugs to Inhibit Sialidase for Sepsis, Escherichia coli vaccine, EV-007156, Glyco-23, HBN-1, HBN-3, HBN-4, HU-003, IFX-1, ImmStem, ImmuneSafe, IND-005, IND-006, IR-999, ISU-201, Klebsiella pneumoniae vaccine, L-97-1, LB-1148, LR-17, M-33, meropenem, Mesenchymal Stem Cells, Metablok, Micselon, Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders, Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease, Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease, Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation, Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease, Nanotherapeutics, NAV-838, OPN-305, Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke, Polysaccharide for Sepsis, Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis, RBM-005, Recombinant Enzyme to Replace Alkaline Phosphatase for Sepsis, Recombinant Human Alkaline Phosphatase, Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation, Recombinant Protein for Sepsis, Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury, Recombinant Protein to Target Lipopolysaccharide for Sepsis, SAN-101, Slit2N, Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease, Small Molecule to Inhibit DDAH1 for Sepsis, Small Molecules for Inflammatory Diseases and Sepsis, Small Molecules to Inhibit NET Formation for Sepsis and SLE, staphylococcus aureus (bivalent) vaccine, Stem Cell Therapy for Autoimmune Diseases, Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases, Synthetic Peptides for Immunology and Infectious Diseases, Synthetic Peptides for Infectious Disease, Synthetic Peptides for Inflammation and Infectious Disorders, Synthetic Peptides for Sepsis, Bacterial and Fungal Infections, Synthetic Peptides to Inhibit LPS for Bacterial and Viral Infections, TF-0003, thrombomodulin alfa, TRX-306, vancomycin hydrochloride and Yersinia pestis vaccine.

On a related note, another research titled EpiCast Report: Sepsis - Epidemiology Forecast to 2023 says in the 6MM, the diagnosed incident cases of sepsis will grow from 1,060,052 cases in 2013 to 1,129,816 cases in 2023, at an Annual Growth Rate (AGR) of 0.66% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed incident cases of sepsis in the 6MM. the sepsis mortality cases will increase from 439,015 cases in 2013 to 531,282 cases in 2023, at an AGR of 2.10% from 2013 to 2023 in the 6MM. Read more at http://www.reportsnreports.com/reports/360204-epicast-report-sepsis-epidemiology-forecast-to-2023.html .

Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]

SOURCE ReportsnReports